JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 20, 2005; DOI: 10.1124/jpet.105.092874


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.092874v1
jpet.105.092874v2
316/1/304    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemarie, A.
Right arrow Articles by Vernhet, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemarie, A.
Right arrow Articles by Vernhet, L.


Received for publication July 19, 2005.
Revised September 14, 2005.
Accepted for publication September 14, 2005.

Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through NF-{kappa}B-related survival pathway downregulation

Anthony Lemarie 1, Claudie Morzadec 1, Delphine Merino 2, Olivier Micheau 2, Olivier Fardel 1, Laurent Vernhet 3*

1 Inserm U620, Faculte de Pharmacie 2 Inserm U517, Facultes de Medecine et Pharmacie 3 INSERM U620, Faculte de Pharmacie

* Address correspondence to: E-mail: laurent.vernhet{at}rennes.inserm.fr

Abstract

Arsenic trioxide (As2O3) is known to be toxic towards leukemia cells. In this study, we determined its effects on survival of human monocytic cells during macrophagic differentiation, an important biological process involved in the immune response. As2O3, used at clinically relevant pharmacological concentrations, induced marked apoptosis of human blood monocytes during differentiation with either granulocyte-macrophage colony-stimulating factor (GM-CSF) or M-CSF. Apoptosis of monocytes was associated with increased caspase activities and decreased DNA binding of p65 NF-{kappa}B; like As2O3, the selective NF-{kappa}B inhibitor Bay 11-7082 strongly reduced survival of differentiating monocytes. The role of NF-{kappa}B in arsenic toxicity was also studied in promonocytic U937 cells during PMA-induced macrophagic differentiation. In these cells, As2O3 first reduced DNA binding of p65 NF-{kappa}B and subsequently induced apoptosis. In addition, overexpression of the p65 NF-{kappa}B subunit, following stable infection with a p65 retroviral expressing vector, increased survival of As2O3-treated U937 cells. As2O3 specifically decreased protein levels of X-linked inhibitor of apoptosis protein (XIAP) and FLICE-inhibitory protein (FLIP), two NF-{kappa}B-regulated genes in both U937 cells and blood monocytes during their differentiation. Finally, As2O3 was found to inhibit macrophagic differentiation of monocytic cells, when used at cytotoxic concentrations; however, overexpression of the p65 NF-{kappa}B subunit in U937 cells reduced its effects towards differentiation. In contrast to monocytes, well-differentiated macrophages were resistant to low concentrations of As2O3. Altogether, our study demonstrates that clinically relevant concentrations of As2O3 induced marked apoptosis of monocytic cells during in vitro macrophagic differentiation likely through inhibition of NF-{kappa}B-related survival pathways.


Key words: NF-kappaB, apoptosis, arsenic, differentiation, human monocytes, macrophages





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.